drugset / Trial / NCT00332774
Nevanac 3-Month Safety Study With QID Dosing
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to determine the safety of Nevanac 0.1% compared to Acular LS 0.4% and Vehicle in patients treated before cataract surgery and for approximately 90 days following surgery.
Timeline
- Start
- 2006-02
- Primary completion
- 2006-12
- Completion
- 2006-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ketorolac | Other / unclassified | 0.4 % | Other |
| Subject | Nepafenac | Other / unclassified | 0.1 % | Other |